J&J’s Vaccine Results Are In. So What’s the Verdict?
The shot appears to work but not as well as hoped, and virus variants may get around it. Still, it’s a valuable addition. Here’s what you need to know.
Eagerly-awaited trial results for J&J’s Covid-19 vaccine pave the way for U.S. approval as soon as next month.
Photographer: Andrey Rudakov/BloombergSam Fazeli, a Bloomberg Opinion contributor who covers the pharmaceutical industry for Bloomberg Intelligence, answered questions about Johnson & Johnson’s Covid-19 vaccine after the drugmaker released results from a large, late-stage trial. The conversation has been edited and condensed.
Johnson & Johnson’s vaccine — a single-shot dose that’s easy to store, unlike others now in use — has been seen as a potential game-changer in the Covid-19 fight, and so these trial results were eagerly anticipated. Are they as good as people were hoping?